Compare WBX & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | LONA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 71.2M |
| IPO Year | 2021 | 2020 |
| Metric | WBX | LONA |
|---|---|---|
| Price | $2.76 | $5.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $17.33 |
| AVG Volume (30 Days) | 12.3K | ★ 455.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $2.21 |
| 52 Week High | $7.60 | $14.21 |
| Indicator | WBX | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 49.07 |
| Support Level | $2.64 | $4.55 |
| Resistance Level | $3.12 | $6.13 |
| Average True Range (ATR) | 0.15 | 1.01 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 54.10 | 77.86 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.